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Abstract 
Zika virus (ZIKV) infection is spreading rapidly within the Americas after originating from an outbreak in Brazil. We describe the current 
ZIKV infection epidemic in Brazil and the neurological symptoms arising. First cases of an acute exanthematic disease were reported in Brazil’s 
Northeast region at the end of 2014. In March 2015, autochthonous ZIKV was determined to be the causative agent of the exanthematic disease. 
As cases of neurological syndromes in regions where ZIKV, dengue and/or Chikungunya viruses co-circulate were reported, ZIKV was also 
identified in the cerebrospinal fluid of patients with acute neurological syndromes and previous exanthematic disease. By the end of September 
2015, an increasing number of infants with small head circumference or microcephaly were noted in Brazil’s Northeast which was estimated 
to be 29 cases between August and October. ZIKV was identified in blood and tissue samples of a newborn and in mothers who had given birth 
to infants with microcephaly and ophthalmological anomalies. In 2015, there were an estimated 440,000 - 1,300,000 Zika cases in Brazil. There 
have been 4,783 suspected cases of microcephaly, most of them in the Northeast of Brazil associated with 76 deaths. The Ministry of Health is 
intensifying control measures against the mosquito Aedes aegypti and implemented intensive surveillance actions. Further studies are needed 
to confirm the suspected association between ZIKV infection and microcephaly; to identify antiviral, immunotherapy, or prophylactic vaccine; 
to introduce diagnostic ELISA testing. Clinical and epidemiological studies must be performed to describe viral dynamics and expansion of 
the outbreak. 
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Introduction 
Zika virus (ZIKV) infection, previously unknown 
to the majority of physicians, public health 
professionals, and policy makers worldwide, is now 
spreading rapidly within the Americas originating from 
an outbreak in Brazil. On 1st February 2016, the World 
Health Organization declared a Public Health 
Emergency of International Concern, considering the 
increasing number of ZIKV infection cases and a 
strongly suspected causal link between ZIKV infection 
and neurological disorders and congenital anomalies, 
which have increased recently in Brazil [1, 2]. By the 
end of January 2016, there have been 18 countries in the 
Americas with confirmed autochthonous cases of Zika 
virus [3]. 
 
The Virus 
ZIKV is a positive-sense, single-stranded 
(nonsegmented) RNA arbovirus of the flaviviridae 
family which is transmitted to humans by a bite from 
mosquitos of the genus Aedes [4,5]. The virus is related 
to other flaviviruses such as yellow fever virus (YFV), 
dengue virus (DENV), and Japanese encephalitis virus, 
but is mostly similar to the Spondweni virus. ZIKV is 
composed of ~10,000 nucleotides which encodes a 
polypeptide protein of ~3,500 aa [6]. 
There are two major lineages of ZIKV, Asian and 
African, which are composed of various sub-clades [5]. 
Although Aedes aegypti is the species of mosquito 
currently most associated with transmission, ZIKV has 
been isolated from a variety of other species of Aedes 
mosquitos including Ae. polynesiensis, Ae. albopictus, 
Ae. hensilli, Ae. africanus, Ae. apicoargenteus, Ae. 
luteocephalus, Ae. vitattus, and Ae. furcifer [5,6]. ZIKV 
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is transmitted to its vector host during the vector’s 
blood meal. Once infected, the virus is then present in 
the vector host for the remainder of its lifespan, where 
it can be transmitted to reservoir hosts during 
subsequent blood meals. 
ZIKV was isolated for the first time in 1947 from a 
sentinel rhesus monkey in the Zika forest of Uganda 
during a jungle fever study [7]. The main mode of 
transmission is considered to be vectorial although 
previous reports have indicated that the virus may be 
transmitted by other means including occupational, 
perinatal, and sexual intercourse [8,9]. 
 
Clinical disease of ZIKV infection 
The clinical presentation defining ZIKV infection is 
difficult to ascertain, as symptomology is often similar 
to that of DENV and Chikungunya virus (CHIKV) 
infections. Reported clinical signs associated with 
ZIKV infection include low grade fever, self-limiting 
rash lasting 4-7 days, conjunctivitis, headache, myalgia, 
and pruritus. Less commonly reported symptoms 
include retro-orbital pain, anorexia, vomiting, diarrhea 
and abdominal pain [5]. Despite the clinical symptoms 
reported, it is suspected that many cases are 
asymptomatic, which is problematic for estimating 
ZIKV infection incidence rates [5]. Before the recent 
outbreaks of the 21st century, no severe complications 
were known, and hospitalization rates associated with 
ZIKV infection were low [10]. 
Diagnosis of ZIKV infection is typically done by 
RT-PCR of RNA isolated from patient blood samples 
collected less than 5 days following the onset of 
symptoms. Viremia in ZIKV patients is reported to 
occur between 3 and 5 days post symptom onset [8]. 
Moreover, live virus and viral RNA have also been 
detected in the semen and urine of Zika infected males 
weeks after initial symptoms and virus clearance in the 
blood. This report possibly suggests that uremia and 
semen viral loads are potentially longer lasting than 
blood viremia [8]. Diagnosis by ELISA is also difficult 
for suspected ZIKV cases, as neutralizing IgM 
antibodies are cross-reactive among the flaviviruses 
especially with DENV serotypes, which may lead to 
false ELISA results (US CDC, Centers for Disease 
Control and Prevention) [11]. Furthermore, cross-
reactivity may also affect retrospective studies aimed at 
determining the existing immunity of a particular 
population. Currently, specific treatments and 
prophylactics such as antivirals and vaccines for ZIKV 
infection and associated diseases do not exist. 
 
Previous ZIKV outbreaks 
Since the first description of ZIKV infection in the 
1940s, the virus was thought to cause mild sporadic 
human infections in Africa and Asia. This picture of 
ZIKV dramatically changed during the large-scale 
epidemics in Micronesia in 2007 and 2013-2014 in Yap 
and French Polynesia and New Caledonia, respectively 
[12-15]. Importantly, these epidemics in Micronesia 
simultaneously occurred along-side dengue fever cases 
(type 1 and 3 serotypes) [14,16]. During these 
outbreaks, neurological complications such as 
meningitis, meningoencephalitis and myelitis were 
reported. The appearance of these neurological 
symptoms were attributed to the concomitant 
circulation of the two dengue serotypes. Moreover, 42 
cases of Guillain-Barré syndrome were diagnosed 
during the French Polynesia outbreak in patients who 
had presented symptoms of ZIKV infection [3,10]. 
 
History of the current outbreak in Brazil 
By the end of 2014, a few months after the Football 
World Cup in Brazil, reports of an acute exanthematic 
disease in various urban centers of Northeastern Brazil 
began to emerge [17,18]. From February 2015 onwards, 
other municipalities began notifying the Brazilian 
Ministry of Health of similar cases in their area. At the 
end of February 2015, the Ministry of Health (Secretary 
of Surveillance – SVS/MS) started monitoring the 
increasing number of an exanthematic disease in the 
Northeast Region of Brazil. All cases were reported to 
be self-limited, without any clinical interventions 
needed [19]. The patients presented with 
maculopapular exanthema, pruritus, low fever (or no 
fever), and in some cases headache, hyperemia of the 
conjunctiva, joint pain, and edema. The most 
commonly affected age group was 20-40 years, with a 
range from 4 months to 98 years of age. 
In March 2015, the Ministry of Health began to 
investigate the source of the outbreak and if the reported 
symptoms were caused by dengue fever, rubella, or 
Chikungunya fever. The preliminary results excluded 
infection by these pathogens. Later that month, ZIKV 
was isolated in Natal, capital of Rio Grande do Norte 
State [20], where 7 of 8 confirmed Zika cases were 
females (mean age 39 years), with similar signs and 
symptoms and fever presenting between 2 to 15 days 
[20]. In two of these cases, the strain of ZIKV was 
determined to be from the Asian lineage. During a 
similar time frame, ZIKV was isolated from samples 
collected from 7 patients with negative serology for 
DENV and CHIKV in the city of Camaçari in Bahia 
State [21,22]. Consequently, in May 2015, the Ministry 
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of Health recognized autochthonous Zika transmission 
in the country, and standardized - in the absence of 
availability of validated ELISA testing – real-time 
polymerase chain reaction (RT-PCR) for the diagnostic 
investigation of suspected cases [19]. 
A few weeks later, in June of 2015, the Ministry of 
Health identified the first cases of neurological 
syndromes with a history of exanthematic disease in 
regions where Zika, dengue and/or Chikungunya 
viruses co-circulate. By the end of that month, the 
Ministry instructed the states of the Brazilian 
Federation to immediately report cases of neurological 
syndromes. Following this instruction, in July of 2015, 
Bahia State also filed cases of Guillain-Barré syndrome 
in patients with a history of exanthematic disease. Of 
the 76 notified Guillain-Barré syndrome cases, 42 were 
confirmed, and 26 (62%) had a previous history of 
ZIKV or DENV infection. In Pernambuco State, ZIKV 
was identified in the cerebrospinal fluid of patients with 
acute neurological syndromes and previous 
exanthematic disease [23,24]. 
By the end of September 2015, reports surfaced of 
an increasing number of infants born with small head 
circumference or microcephaly from various healthcare 
facilities in Pernambuco State in the Northeast region 
(2 to 3 standard deviations below average for age and 
gender) [25]. By October, the State Health Secretariat 
of Pernambuco State (SES/PE) notified 29 cases of 
microcephaly in infants born since August. Taken 
together, these findings represent an extreme increase 
in microcephaly as compared to previous years [25,26]. 
On the 23rd October 2015, the Brazilian Ministry of 
Health notified the World Health Organization about 
the occurrence of the increased number of infant 
microcephaly. On 12th November, the Ministry of 
Health of Brazil published an order declaring a Public 
Health Emergency of National Importance 
(Emergência de Saúde Pública de importância 
Nacional - ESPIN), and on 17th November, a technical 
note was also published. On 24th November, ZIKV was 
identified in blood and tissue samples of a newborn 
from Ceará State, that had died in the postpartum period 
(Pamplona, personal communication 2016). After this 
incident, ZIKV was also isolated from the umbilical 
cord of a newborn and the Ministry of Health declared 
a possible association between ZIKV infection and the 
increasing number of microcephaly cases [27]. In 
Figure 1. Distribution of reported cases of ZIKV infection in 
Brazil by state, from the beginning of the outbreak (December 
2014) until the end of January 2016. 
Figure 2. Distribution of reported cases of microcephaly in 
Brazil from July 2015 to February 2016. 
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December 2015, guidelines for the management of 
microcephaly were published by the Ministry of Health 
[26]. In January 2016, three infants whose mothers had 
a history of ZIKV infection were diagnosed with 
microcephaly and ophthalmological anomalies. 
Additionally, one child also displayed neuroretinal 
atrophy [24].  
It has been estimated that in 2015 there were 
between 440,000 and 1,300,000 Zika cases in Brazil. 
By 1st February 2016, autochthonous cases of ZIKV 
were identified in 22 states of the Federation (Figure 1). 
Since the beginning of the outbreak, there have been 
5,280 suspected cases of microcephaly, most of them in 
the Northeast of Brazil (Figure 2), with 108 deaths. By 
13th February 2016, 1,345 of the notified suspected 
cases had been investigated and classified, with 508 
confirmed cases of microcephaly. In contrast, during 
the time period between 2010 and 2014, the annual 
mean of microcephaly cases reported in Brazil was 163. 
The main vector carrying the ZIKV in Brazil has 
been identified as Aedes aegypti, the same mosquito 
species, which transmits DENV and CHIKV in Brazil. 
The Ministry of Health is currently intensifying control 
measures against the mosquito vector and implemented 
surveillance actions to identify possible areas of 
transmission as early as possible. Furthermore, 
neurological syndromes and congenital anomalies are 
under strict government surveillance. By Presidential 
Decree from 21st December 2015, a National Task 
Force was installed, consisting of representatives from 
various Ministries, coordinated by the Ministry of 
Health [28]. The Brazilian Army was mobilized to 
support the community health agents in mosquito 
control measures, consisting of house-to-house visits 
and elimination of possible Ae. aegypti breeding sites. 
The aim is to visit all urban households in Brazil by the 
end of February 2016. 
The co-circulation of ZIKV, DENV, and CHIKV in 
overlapping endemic regions of Brazil calls for special 
attention and highlights the urgent need for systematic 
studies and further laboratory, clinical, and 
epidemiological research. 
 
Future outlooks 
At this time, the current situation in Brazil leaves 
scientists, health care workers, and political leaders 
with addressing urgent action items, which encompass 
transmission, pathogenesis, and treatment of ZIKV. 
Most importantly, the suspected association between 
ZIKV infection and microcephaly must be confirmed 
scientifically. To decrease the expansion of ZIKV and 
its associated infection rate, the extremely rapid spread 
of the outbreak to other regions must be controlled. 
Currently, there is no specific treatment for ZIKV 
infection which prompts the identification of an 
antiviral, immunotherapy, or prophylactic vaccine. As 
ELISA testing is still not available, the estimation of 
ZIKV infected individuals is not feasible. It is essential 
to introduce a Zika antibody ELISA testing kit on a 
large scales as fast as possible. Finally, there are only 
very limited clinical and epidemiological data including 
the geographical spread and expansion of the outbreak. 
We need to have a better understanding of the viral 
dynamics in the environment and human population to 
design appropriate and effective control measures. 
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